Should Tumor Infiltrating Lymphocytes, Androgen Receptor, and FOXA1 Expression Predict the Clinical Outcome in Triple Negative Breast Cancer Patients?
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Should Tumor Infiltrating Lymphocytes, Androgen Receptor, and FOXA1 Expression Predict the Clinical Outcome in Triple Negative Breast Cancer Patients?
Authors
Keywords
-
Journal
Cancers
Volume 11, Issue 9, Pages 1393
Publisher
MDPI AG
Online
2019-09-18
DOI
10.3390/cancers11091393
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Therapeutic cooperation between auranofin, a thioredoxin reductase inhibitor and anti‐PD‐L1 antibody for treatment of triple‐negative breast cancer
- (2019) PV Raninga et al. INTERNATIONAL JOURNAL OF CANCER
- Independent Negative Prognostic Role of TCF1 Expression within the Wnt/β-Catenin Signaling Pathway in Primary Breast Cancer Patients
- (2019) Saponaro et al. Cancers
- PD-L1 Blockade by Atezolizumab Downregulates Signaling Pathways Associated with Tumor Growth, Metastasis, and Hypoxia in Human Triple Negative Breast Cancer
- (2019) Reem Saleh et al. Cancers
- Diffuse distribution of tumor-infiltrating lymphocytes is a marker for better prognosis and chemotherapeutic effect in triple-negative breast cancer
- (2019) Akira I. Hida et al. BREAST CANCER RESEARCH AND TREATMENT
- Prognostic value of androgen receptor and FOXA1 co-expression in non-metastatic triple negative breast cancer and correlation with other biomarkers
- (2018) Séverine Guiu et al. BRITISH JOURNAL OF CANCER
- Checkpoint inhibitors in breast cancer – Current status
- (2018) Anne Polk et al. CANCER TREATMENT REVIEWS
- NHERF1 and tumor microenvironment: a new scene in invasive breast carcinoma
- (2018) Concetta Saponaro et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- A Comprehensive Immunologic Portrait of Triple-Negative Breast Cancer
- (2018) Zhixian Liu et al. Translational Oncology
- Clinical significance of androgen receptor expression in triple negative breast cancer‑an immunohistochemistry study
- (2018) Ya‑Xuan Liu et al. Oncology Letters
- Immunotherapy for colorectal cancer: where are we heading?
- (2017) Debora Basile et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- NHERF1 together with PARP1 and BRCA1 expression as a new potential biomarker to stratify breast cancer patients
- (2017) Anita Mangia et al. Oncotarget
- Prognostic significance of PD-L1 expression and tumor infiltrating lymphocyte in surgically resectable non-small cell lung cancer
- (2017) Gen Lin et al. Oncotarget
- The combination of PD-L1 expression and decreased tumor-infiltrating lymphocytes is associated with a poor prognosis in triple-negative breast cancer
- (2017) Hitomi Mori et al. Oncotarget
- Expression and Clinical Significance of Androgen Receptor in Triple-Negative Breast Cancer
- (2017) Yuka Asano et al. Cancers
- Prognostic value of FOXA1 in breast cancer: A systematic review and meta-analysis
- (2016) Jiafeng Shou et al. BREAST
- Tumor-infiltrating lymphocytes (TILs) are a powerful prognostic marker in patients with triple-negative breast cancer enrolled in the IBCSG phase III randomized clinical trial 22-00
- (2016) Giancarlo Pruneri et al. BREAST CANCER RESEARCH AND TREATMENT
- Biology and Management of Patients With Triple-Negative Breast Cancer
- (2016) P. Sharma ONCOLOGIST
- Prognostic value of androgen receptor in triple negative breast cancer: A meta-analysis
- (2016) Changjun Wang et al. Oncotarget
- NHERF1 regulates the progression of colorectal cancer through the interplay with VEGFR2 pathway
- (2016) Yanan Gu et al. Oncotarget
- Immune inflammation indicators and implication for immune modulation strategies in advanced hepatocellular carcinoma patients receiving sorafenib
- (2016) Andrea Casadei Gardini et al. Oncotarget
- Variation in the Incidence and Magnitude of Tumor-Infiltrating Lymphocytes in Breast Cancer Subtypes
- (2016) Sasha E. Stanton et al. JAMA Oncology
- The Prognostic Value of Tumor-Infiltrating Lymphocytes in Breast Cancer: A Systematic Review and Meta-Analysis
- (2016) Yan Mao et al. PLoS One
- Prognostic and predictive value of tumor-infiltrating lymphocytes in breast cancer: a systematic review and meta-analysis
- (2015) X. Yu et al. Clinical & Translational Oncology
- Influence of Androgen Receptor Expression on the Survival Outcomes in Breast Cancer: A Meta-Analysis
- (2015) Yoonseok Kim et al. Journal of Breast Cancer
- Proper genomic profiling of (BRCA1 -mutated) basal-like breast carcinomas requires prior removal of tumor infiltrating lymphocytes
- (2015) Maarten P.G. Massink et al. Molecular Oncology
- Nuclear PARP1 expression and its prognostic significance in breast cancer patients
- (2015) Annalisa Mazzotta et al. TUMOR BIOLOGY
- Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study
- (2014) M. V. Dieci et al. ANNALS OF ONCOLOGY
- The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014
- (2014) R. Salgado et al. ANNALS OF ONCOLOGY
- Androgen Receptor Expression Predicts Decreased Survival in Early Stage Triple-Negative Breast Cancer
- (2014) Jung Eun Choi et al. ANNALS OF SURGICAL ONCOLOGY
- US Incidence of Breast Cancer Subtypes Defined by Joint Hormone Receptor and HER2 Status
- (2014) Nadia Howlader et al. JNCI-Journal of the National Cancer Institute
- FOXA1 repression is associated with loss of BRCA1 and increased promoter methylation and chromatin silencing in breast cancer
- (2014) C Gong et al. ONCOGENE
- Androgen Receptor-Positive Triple Negative Breast Cancer: A Unique Breast Cancer Subtype
- (2013) Lee J. McGhan et al. ANNALS OF SURGICAL ONCOLOGY
- Androgenic pathway in triple negative invasive ductal tumors: Its correlation with tumor cell proliferation
- (2013) Keely M. McNamara et al. CANCER SCIENCE
- Androgen Receptor Expression and Outcomes in Early Breast Cancer: A Systematic Review and Meta-Analysis
- (2013) F. E. Vera-Badillo et al. JNCI-Journal of the National Cancer Institute
- Nuclear NHERF1 expression as a prognostic marker in breast cancer
- (2013) A Paradiso et al. Cell Death & Disease
- FOXA1 is an independent prognostic marker for ER-positive breast cancer
- (2011) Rutika J. Mehta et al. BREAST CANCER RESEARCH AND TREATMENT
- Targeting Androgen Receptor in Estrogen Receptor-Negative Breast Cancer
- (2011) Min Ni et al. CANCER CELL
- Behavior of seeds and soil in the mechanism of metastasis: A deeper understanding
- (2011) Lucy Mathot et al. CANCER SCIENCE
- Androgen receptor driven transcription in molecular apocrine breast cancer is mediated by FoxA1
- (2011) Jessica L L Robinson et al. EMBO JOURNAL
- 'Hide-then-hit' to explain the importance of genotypic polymorphism of DNA repair genes in determining susceptibility to cancer
- (2011) P.-E. Wu et al. Journal of Molecular Cell Biology
- FOXA1 is a key determinant of estrogen receptor function and endocrine response
- (2010) Antoni Hurtado et al. NATURE GENETICS
- Androgen receptor overexpression induces tamoxifen resistance in human breast cancer cells
- (2009) Francesca De Amicis et al. BREAST CANCER RESEARCH AND TREATMENT
- Tumor-Associated Lymphocytes As an Independent Predictor of Response to Neoadjuvant Chemotherapy in Breast Cancer
- (2009) Carsten Denkert et al. JOURNAL OF CLINICAL ONCOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now